Search
Anthrax immune globulin human
go.drugbank.com/drugs/DB09057ApprovedInvestigationalIt is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue … It is derived from the plasma of humans immunized with BioThrax (adsorbed anthrax vaccine), which is then further purified.
Ethylhexyl methoxycrylene
go.drugbank.com/drugs/DB11226ApprovedIt currently enjoys regional approvals in Canada, the EU, and the US [L2847]. … It is used as a solvent for crystalline UV filters and is easily emulsified and suitable for use in various lotions, creams, sprays, sticks, and gel formulations [F104].
Fosdenopterin
go.drugbank.com/drugs/DB16628Approved[A230088] MoCD is incurable and median survival in untreated patients is approximately 36 months[A230088] - treatment, then, is focused on improving survival and maintaining neurological function. … [L43075] In September 2022, the EMA approved the use of fosdenopterin.[L43372,L43433]
Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in the elderly. … Sutimlimab is a first-in-class humanized monoclonal antibody targeted at complement subunit C1s, which is responsible for activating the classic complement pathway.
Maraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalIt was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the
Trioxsalen
go.drugbank.com/drugs/DB04571ApprovedWithdrawnThe photoactivated form produces interstrand linkages in DNA resulting in cell apoptosis. … It is administered either topically or orally in conjunction with UV-A (the least damaging form of ultraviolet light) for phototherapy treatment of vitiligo and hand eczema.
Ethambutol
go.drugbank.com/drugs/DB00330ApprovedInvestigational[L31743] Ethambutol was first described in the literature in 1961.[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_. … Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis.
Synonyms: (+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamineRegdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawn[A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130] … Trials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020.
Orforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigationalOrforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. … [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations.
Tiotropium
go.drugbank.com/drugs/DB01409ApprovedInvestigationalTiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. … [A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium].